Patent number: 6777407
Abstract: This invention provides compounds of the formulae:
wherein:
R1 is hydrogen, —C(O)CH3 or alkyl of 1-6 carbon atoms;
R2 and R3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl, alkoxy of 1-6 carbon atoms, —CH2OH, fluoroalkyl, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, fluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, aryl, or aroyl;
R4 and R5 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, fluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, fluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
R6 and R7 are each independently hydrogen, C1-C6 alkyl or cycloalkyl;
or a pharmaceutically acceptable salt thereof, as well as pharmaceut
Type:
Grant
Filed:
November 2, 2001
Date of Patent:
August 17, 2004
Assignee:
Wyeth
Inventors:
Annmarie Louise Sabb, Robert Lewis Vogel, James Albert Nelson, Sharon Joy Rosenzweig-Lipson, Gregory Scott Welmaker, Joan Eileen Sabalski
Patent number: 6476032
Abstract: This invention provides compounds of formula I,
wherein
R is hydrogen or alkyl of 1-6 carbon atoms;
R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
X is CR5R6 or a carbonyl group;
R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen;
which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorde
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
November 5, 2002
Assignee:
Wyeth
Inventors:
Sharon Joy Rosenzweig-Lipson, Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson